Order Summary

In order to access content on the Celltelligence Library, you must have an account.

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.

Account Information Already have an account? Log in here


By selecting this, I agree to receive emails from celltelligence.com.

You will be granted access to your Celltelligence Library to view the full article after sign up.

Could Yescarta in 2L LBCL Receive a CHMP Positive Opinion This Week?

Here is a brief preview of this blast: On Monday, May 16, the CHMP agenda for May was released. Of note, Yescarta in 2L LBCL has been listed as for adoption under ‘Type II variations - variation of therapeutic indication’.

About The Author

The Celltelligence Team

Content Leads & Contributors
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.